Findings showed that RiboCeine supplementation
elevates serum glutathione levels, with more pronounced effects in
older participants
LOS
ANGELES, April 25, 2024 /PRNewswire/ -- PRUVN
Research LLC, [PRUVN], a leading research organization validating
wellness products and services, is excited to announce the results
of its recent preliminary study with Max International,
investigating the impact of
RiboCeine™ supplementation on serum glutathione
levels. Glutathione, the master antioxidant in cellular defense
against oxidative stress, has garnered significant awareness in the
wellness and longevity industry for its potential health benefits
with more than 180,000 research articles on glutathione currently
listed on the US National Library of Medicine database.
...a preliminary study like this matters
because it provides empirical evidence of the product's potential
benefits...
The PRUVN™ preliminary study, involving 40 participants
randomly selected aged 38 to 60, revealed promising trends
indicating that RiboCeine supplementation elevated serum
glutathione levels, with more pronounced effects in older
participants.
"At Max International, we are dedicated to excellence and put
our products to scientific scrutiny to prove to consumers that Max
has the best products on the market," Joe
Voyticky, Executive Chairman of Max International said,
adding that "consumers care about actual, legitimate proof that the
products they buy are scientifically validated."
For the past three decades, researchers have conducted 55
peer-reviewed, independent clinical studies on Max International's
patented "cornerstone" compound, primarily using animal models.
However, recognizing the need for human clinical trials to further
their findings, Max International turned to PRUVN to embark on this
next research phase.
Elias Arjan, CEO and Co-Founder
at PRUVN, said that one of PRUVN's core competencies is providing
the opportunity for companies to transition from animal models to
human clinical trials in a way that's efficient, cost-effective and
scientifically valid. "When a company has already conducted
preclinical trials, whether it's animal models, cell cultures, or
in silico via a computer simulation, we don't have to worry whether
the compound has an impact, but rather we can focus on its efficacy
in a real-world setting, and ultimately that's what matters most to
customers."
The supplement industry is witnessing a paradigm shift where
consumers are no longer satisfied with mere promises, but seek
tangible scientific evidence that validate product efficacy.
Additionally, regulatory agencies are moving toward requiring that
companies provide comprehensive lists of ingredients and credible
scientific evidence to substantiate their product claims. This
increased demand from both consumers and authorities means that
companies that proactively adapt, embrace transparency and invest
in robust scientific research, will gain significant competitive
advantage.
Voyticky underscored, "It is the obligation of companies in the
supplement industry to ensure the general public that their
products actually work."
From a customer's perspective, a preliminary study like this
matters because it provides empirical evidence of the product's
potential benefits, in this case, increasing serum glutathione
levels, which is associated with enhanced antioxidant defense.
"It demonstrates a supplement's ability to produce a beneficial
effect, which can influence customer decision-making, enhance the
brand's reputation and increase customer confidence in the
product," Francisco Cidral, Chief
Scientific Officer and Co-Founder at PRUVN, explained, adding that
"it serves as a differentiator in a crowded market, where many
products may not have substantial scientific backing."
Max International's team shared that they remain committed to
pursuing additional studies to determine definitive evidence of
RiboCeine's role in increasing glutathione levels and additional
potential benefits.
Bobbi Horne, Vice President
Healthcare Professional Division at Max International, reiterated
the company's dedication to scientific research and meeting
consumer expectations, stating that "we see it as an obligation to
the consumer to produce supplements with the highest quality
ingredients, in formulations that work."
Study design:
The double-blinded, placebo-controlled human clinical trial was
approved by the University of Santa Catarina Ethics Committee and
involved 40 participants aged 38 to 60. Participants were
randomized into two groups to receive either placebo or RiboCeine
supplementation (250 mg daily) for four weeks. Serum glutathione
levels were measured at baseline and post-supplementation using a
Spectrophotometric Assay (SpectraMax). The study further analyzed
the impact of age on glutathione levels by dividing participants
into two age groups: 38-50 and 51-60.
Key findings:
The placebo group exhibited a decrease in serum glutathione
levels across all age groups, with a higher drop in older
participants. In contrast, the RiboCeine™ group experienced a
significant 26.6% overall increase in serum glutathione levels,
with a more pronounced increase of 64.7% in the older age group. To
investigate beyond this initial evidence of effectiveness, as a
next step, PRUVN's science team recommended further research with a
larger sample size to reach a comprehensive validation.
The big reveal on the Going Public TV show:
The PRUVN study's findings, including the journey of Max
International partnering with PRUVN for this human trial, will be
unveiled on the Going Public TV show in May
2024. This segment will provide viewers with a firsthand
account of the process behind investigating product efficacy and
highlight both companies' dedication to scientific rigor.
About PRUVN Research LLC
PRUVN™ is a pioneering company dedicated to transforming the
wellness and longevity industry by providing a service for brands
to validate their products through rigorous scientific evaluation.
PRUVN's mission is to empower consumers to make evidence-based
decisions about their health and well-being. PRUVN is currently
recruiting for studies that are open to the general public to join.
Click here to participate in one of the upcoming PRUVN studies. For
more information on PRUVN, please visit www.pruvn.io and follow the
company's LinkedIn page for the latest news and updates.
About Max International
Established in 2007, Max International is committed to improving
quality of life through their scientifically formulated and
validated health products. Operating in over 20 countries, Max
International continues to expand its reach, helping individuals
achieve their health goals through innovative and effective
supplements. For more information, visit www.livemax.com or
www.RiboseCysteine.com
Note to Editors:
For high-resolution images, additional information, or interview
requests, please contact media@pruvn.io
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pruvn-reveals-human-clinical-trial-results-of-max-internationals-riboceine-supplementations-impact-on-serum-glutathione-levels-302126752.html
SOURCE PRUVN